Table 1. The baseline characteristics of 195 hepatocellular carcinoma patients.
| Variables | N (%) or median (range), n=195 |
|---|---|
| Gender (male/female) | 174 (89.2%)/21 (10.8%) |
| Age, years | 51 (42, 59) |
| Cirrhosis (absent/present) | 69 (35.4%)/126 (64.6%) |
| Tumor diameter (cm) | 4.4 (3.0, 7.5) |
| Tumor number (single/multiple) | 147 (75.4%)/48 (24.6%) |
| Vascular invasion (absent/present) | 115 (59.0%)/80 (41.0%) |
| BCLC stage (0~A/B/C) | 98 (50.3%)/77 (39.5%)/20 (10.3%) |
| Pathological differentiation (well/poor-moderate) | 26 (13.3%)/169 (86.7%) |
| Intraoperative blood transfusion (absent/present) | 99 (50.8%)/96 (49.2%) |
| AFP, ng/mL (≤400/>400) | 130 (66.7%)/65 (33.3%) |
| Fibrinogen, g/L | 3.01 (2.43, 3.65) |
| Platelet, ×109/L | 175 (124, 231) |
| Alanine aminotransferase, U/L | 36 (26, 53) |
| Albumin, g/L | 39.6 (37.5, 42.5) |
| Glutamyl transpeptidase, U/L | 63.0 (35.0, 98.0) |
| Pre-NLR | 1.95 (1.12, 2.12) |
| NLR (4–8 w) | 1.47 (1.12, 2.12) |
| NLR (3–6 m) | 1.62 (1.14, 2.44) |
BCLC, Barcelona clinic liver cancer; AFP, α-fetoprotein; NLR, neutrophil-to-lymphocyte ratio; Pre-NLR, preoperative NLR.